IL2 and lung carcinoma: CD4+ T cells activated using anti-CD3, followed by liposomal IL-2 administration, achieved tumor remissions and extended disease-free survival in mice with MC-38 colon adenocarcinoma, 3LL lung carcinoma, or 38C13 lymphoma [155].